CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2021-07-16
Target enrollment:
Participant gender:
Summary
This clinical trial is a randomized Phase 2 evaluation of CB-839 (telaglenastat) in
combination with cabozantinib versus placebo with cabozantinib in patients with advanced or
metastatic Renal Cell Carcinoma with a clear cell component.